Search results
Results from the WOW.Com Content Network
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.It is made up of the following drugs: [1] FOL – folinic acid (), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
Adjuvant treatment in patients with stage III colon cancer is recommended [2] for 12 cycles, every two weeks. The recommended dose schedule is as follows: Day 1: Oxaliplatin 85 mg/m 2 intravenous (IV) infusion in 250-500 mL D5W and leucovorin 200 mg/m 2 IV infusion in D5W administered concurrently over 120 minutes in separate bags using a Y-line, followed by fluorouracil (5-FU) 400 mg/m 2 IV ...
IFL is a chemotherapy regimen for treatment of certain cancers, consisting of concurrent treatment with irinotecan, leucovorin (folinic acid), and fluorouracil. [1] It is similar to the FOLFIRI regimen and uses the same drugs. However, the fluorouracil component is given as a bolus injection rather than as an infusion over 48 hours. [1]
Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. [3] By intravenous injection it is used for treatment of colorectal cancer, oesophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. [3]
[23] [25] In the 5-FU clinical study cited above, people whose dose was adjusted to achieve a pre-determined target exposure realized an 84% improvement in treatment response rate and a six-month improvement in overall survival (OS) compared with those dosed by BSA. [23] 5-FU dose management avoids serious side effects experienced with BSA ...
Also, the doses (Day 1: irinotecan 165 mg/m2 IV, plus oxaliplatin 85 mg/m2 IV; Day 1: leucovorin 400 mg/m2; Days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) [1] [8] [9] are slightly dissimilar to FOLFIRINOX.
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. [1] It was patented in 1967 and approved for medical use in 1972. [2]
Fluorodeoxyuridylate, [1] also known as FdUMP, 5-fluoro-2'-deoxyuridylate, and 5-fluoro-2'-deoxyuridine 5'-monophosphate, is a molecule formed in vivo from 5-fluorouracil and 5-fluorodeoxyuridine. FdUMP acts as a suicide inhibitor of thymidylate synthase (TS).